Oruka Therapeutics (ORKA) Return on Capital Employed (2011 - 2024)
Oruka Therapeutics' (ORKA) quarterly Return on Capital Employed came in at 26.85% in Q2 2024, down 716.0% year-on-year from 4.36% in Q3 2023, and down 20.11% quarter-over-quarter from 22.36% in Q1 2024.
Oruka Therapeutics (ORKA) Return on Capital Employed (2011 - 2024) Analysis & Trends
Oruka Therapeutics' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 26.85% for Q2 2024.
- On a quarterly basis, Return on Capital Employed fell 716.0% year-over-year to 26.85% in Q2 2024; TTM through Jun 2024 was 26.85%, a 716.0% decrease from a year earlier, with the FY2023 full-year figure at 18.32%, up 382.0% from the prior year.
- Return on Capital Employed retreated to 26.85% in Q2 2024 per ORKA's latest filing, from 22.36% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18.53% in Q3 2023 and bottomed at 78.51% in Q1 2020.
- The 5-year median for Return on Capital Employed is 24.98% (2021), against an average of 30.86%.
- Biggest YoY gain for Return on Capital Employed was 5650 bps in 2021; the steepest drop was 1529 bps in 2021.
- Year by year, Return on Capital Employed stood at 20.47% in 2020, then plunged by 75 bps to 35.77% in 2021, then surged by 31 bps to 24.7% in 2022, then increased by 22 bps to 19.26% in 2023, then sank by 39 bps to 26.85% in 2024.
- Per Business Quant, the three latest ORKA Return on Capital Employed figures stand at 26.85% (Q2 2024), 22.36% (Q1 2024), and 19.26% (Q4 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Oruka Therapeutics | 36.09 Mn | -795.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -26.85% |
| Mar 31, 2024 | -22.36% |
| Dec 31, 2023 | -19.26% |
| Sep 30, 2023 | -18.53% |
| Jun 30, 2023 | -19.69% |
| Mar 31, 2023 | -22.07% |
| Dec 31, 2022 | -24.70% |
| Sep 30, 2022 | -33.03% |
| Jun 30, 2022 | -36.13% |
| Mar 31, 2022 | -36.84% |
| Dec 31, 2021 | -35.77% |
| Sep 30, 2021 | -31.52% |
| Jun 30, 2021 | -25.26% |
| Mar 31, 2021 | -22.01% |
| Dec 31, 2020 | -20.47% |
| Sep 30, 2020 | -19.54% |
| Jun 30, 2020 | -62.96% |
| Mar 31, 2020 | -78.51% |
| Dec 31, 2019 | -69.91% |
| Sep 30, 2019 | -67.23% |